Cardiac Biomarkers Testing Market Report 2025

The cardiac biomarkers testing market size has grown rapidly in recent years. It will grow from $13.48 billion in 2024 to $15.09 billion in 2025 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to increasing incidence of cardiovascular diseases, aging population, awareness and education initiatives, government initiatives and healthcare policies, increasing healthcare expenditure.

The cardiac biomarkers testing market size is expected to see rapid growth in the next few years. It will grow to $23.75 billion in 2029 at a compound annual growth rate (CAGR) of 12%. The growth in the forecast period can be attributed to personalized medicine, rising global burden of cardiovascular diseases, integration of artificial intelligence (ai) in diagnostics, expansion of point-of-care testing, increasing emphasis on early disease detection. Major trends in the forecast period include technological advancements, advancements in ai-assisted diagnostics, point-of-care testing (POCT) growth, multiplexing capabilities, biomarker discovery and validation.

The anticipated rise in the prevalence of cardiovascular diseases is poised to drive the growth of the cardiac biomarkers testing market. Cardiovascular diseases, impacting the heart or blood vessels, necessitate quick and accurate diagnostic tools. Cardiac biomarker tests play a crucial role by assessing biomarker levels to promptly determine the severity and magnitude of a heart attack. As indicated by data from the American College of Cardiology in August 2022, the United States is expected to witness a considerable increase in the rates of cardiovascular risk factors and diseases by the year 2060. This projection underscores the anticipated surge in demand for cardiac biomarker testing solutions, aligning with the overall growth of the cardiac biomarkers testing market.

The growing demand for personalized medical solutions emerges as a significant driver propelling the cardiac biomarkers testing market forward. Personalized medicine, tailoring medical decisions and interventions to individual patients, is increasingly incorporating cardiac biomarkers testing for more precise cardiovascular care. This integration enhances prevention, early detection, and treatment strategies, addressing the specific needs of each patient. Notably, reports from October 2022 indicate a significant presence of over 75,000 genetic testing products and 300 personalized medicines, reflecting the expanding demand for personalized medicine solutions. This trend contributes to the sustained growth of the cardiac biomarkers testing market.

Major companies in the cardiac biomarker testing market are making strides in modern cardiovascular diagnostics to enhance the early detection, accuracy, and monitoring of heart-related conditions. These advancements aim to improve test sensitivity, decrease turnaround times, and provide more comprehensive insights into heart health, ultimately leading to better patient outcomes and more effective treatment plans. For example, in October 2023, Mindray Medical International Limited, a China-based medical device company, introduced high-sensitivity troponin I (hs-cTnI) and NT-proBNP to improve the diagnosis and management of cardiovascular diseases. High-sensitivity cardiac troponin I (hs-cTnI) is a protein that enters the bloodstream when the heart muscle sustains damage. NT-proBNP is a peptide produced by the heart in response to increased ventricular volume and pressure overload. The innovative features of hs-cTnI include its ability to detect low levels of cardiac troponin, which enhances the early diagnosis of myocardial infarction, while NT-proBNP offers critical insights into the severity of heart failure through its reaction to ventricular stress. These biomarkers significantly enhance clinical decision-making and patient outcomes in cardiovascular care.

Prominent companies in the cardiac biomarker testing market are strategically focusing on innovative products, with a particular emphasis on cardiac biomarkers, to drive revenue growth. Cardiac biomarkers, also referred to as cardiac enzymes, are substances released into the bloodstream in response to heart muscle damage, serving as crucial indicators in diagnosing and monitoring cardiovascular conditions. In October 2023, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a China-based company specializing in medical equipment and solutions, launched troponin I (hs-cTnI) and NT-proBNP cardiac biomarkers. The hs-cTn assay surpasses minimal requirements for sensitivity, accuracy, and reliability in identifying myocardial damage. These innovative products aim to enhance treatment for cardiovascular illnesses, providing reliable solutions that improve patient outcomes both within and beyond the realm of cardiovascular diseases.

In July 2024, Roche Holding AG, a pharmaceutical company based in Switzerland, acquired LumiraDx’s Point of Care technology for an undisclosed amount. This acquisition aims to bolster Roche's diagnostic portfolio, especially in the realm of decentralized diagnostics. By incorporating LumiraDx’s innovative point-of-care platform, Roche intends to enhance its capacity to deliver rapid and accurate testing at or near patient locations. LumiraDx Ltd., a healthcare company located in the UK, specializes in providing cardiac biomarker testing, including the NT-proBNP test.

Major companies operating in the cardiac biomarkers testing market include Abbott Laboratories, Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Biomérieux SA, Becton Dickinson and Company, Randox Laboratories Ltd., Enzo Biochem Inc., Creative Diagnostics Inc., Merck Co. & KGaA, Beckman Coulter Inc., QIAGEN N.V., PerkinElmer Inc., Tosoh Corporation, Eurolyser Diagnostica GmbH, Cortez Diagnostics Inc., DIALAB GmbH, CardioGenics Holdings Inc., Lepu Medical Technology (Beijing) Co. Ltd., Biosynex SA, Charles River Laboratories, Quidel Corporation, Life Diagnostics, Trinity Biotech plc, Guangzhou Wondfo Biotech Co. Ltd., Nova Biomedical Corp., Ortho Clinical Diagnostics Inc., Sekisui Diagnostics Inc., Abcam plc, Bio-Techne Corporation.

North America was the largest region in the cardiac biomarkers testing market in 2024. The regions covered in the cardiac biomarkers testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiac biomarkers testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiac biomarkers testing involves assessing the levels of specific substances in the blood, aiding in the diagnosis, evaluation, and monitoring of individuals possibly experiencing acute coronary syndrome (ACS).

Key biomarkers in cardiac biomarkers testing include creatine kinase (CK-MB), troponins, myoglobin, natriuretic peptides (BNP and NT-proBNP), ischemia-modified albumin (IMA), and various others. Creatine kinase (CK-MB) is an enzyme analyzed through a blood test. These tests find applications in conditions such as congestive heart failure, acute coronary syndrome, myocardial infarction, atherosclerosis, among others, primarily utilized by hospitals and specialized clinics.

The cardiac biomarkers testing market research report is one of a series of new reports that provides cardiac biomarkers testing market statistics, including cardiac biomarkers testing industry global market size, regional shares, competitors with cardiac biomarkers testing market share, detailed cardiac biomarkers testing market segments, market trends, and opportunities, and any further data you may need to thrive in the cardiac biomarkers testing industry. This cardiac biomarkers testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The cardiac biomarkers testing market includes revenues earned by entities by providing ischemia-modified albumin (IMA), peptides, and C-reactive protein (CRP) biomarkers testing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.